Crinetics Pharmaceuticals, Inc.
CRNX
$34.47
-$0.57-1.63%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.04M | 1.04M | 1.39M | 1.97M | 4.01M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.04M | 1.04M | 1.39M | 1.97M | 4.01M |
| Cost of Revenue | 240.16M | 219.17M | 201.10M | 183.40M | 168.53M |
| Gross Profit | -239.12M | -218.13M | -199.72M | -181.43M | -164.51M |
| SG&A Expenses | 99.74M | 88.64M | 78.23M | 66.73M | 58.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 339.89M | 307.81M | 279.33M | 250.13M | 226.62M |
| Operating Income | -338.85M | -306.77M | -277.95M | -248.16M | -222.61M |
| Income Before Tax | -298.41M | -277.91M | -258.54M | -235.46M | -214.53M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -298.41 | -277.91 | -258.54 | -235.46 | -214.53 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -298.41M | -277.91M | -258.54M | -235.46M | -214.53M |
| EBIT | -338.85M | -306.77M | -277.95M | -248.16M | -222.61M |
| EBITDA | -336.07M | -304.51M | -276.19M | -246.87M | -221.51M |
| EPS Basic | -3.70 | -3.72 | -3.77 | -3.77 | -3.70 |
| Normalized Basic EPS | -2.31 | -2.32 | -2.36 | -2.36 | -2.31 |
| EPS Diluted | -3.71 | -3.72 | -3.77 | -3.78 | -3.70 |
| Normalized Diluted EPS | -2.31 | -2.32 | -2.36 | -2.36 | -2.31 |
| Average Basic Shares Outstanding | 322.88M | 298.53M | 275.25M | 250.52M | 232.14M |
| Average Diluted Shares Outstanding | 322.88M | 298.53M | 275.25M | 250.52M | 232.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
